A cardiac organoid containing 3-D matter of adult human heart tissue.

A production method for a proliferative liver organoid includes culturing liver stem cells or a tissue fragment including liver stem cells in a growth medium to obtain a proliferative liver organoid, in which the growth medium contains an interleukin-6 family cytokine. A production method for a metabolically activated liver organoid includes culturing the proliferative liver organoid produced by the production method for a proliferative liver organoid in a differentiation medium to obtain a metabolically activated liver organoid, in which the differentiation medium does not substantially contain an interleukin-6 family cytokine.

Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent renal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological renal tubule model. Also disclosed are methods of assessing the effect of an agent on renal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological renal tubule model. Also disclosed are models of renal disorder. In one embodiment, disclosed are models of renal fibrosis, comprising a three-dimensional, engineered, bioprinted, biological renal tubule model. Also disclosed are methods of making the model of renal disorder. In one embodiment disclosed are methods of making the model of renal fibrosis comprising contacting a three-dimensional, engineered, bioprinted, biological renal tubule model with an agent that is capable of inducing interstitial fibrotic tissue formation.

The present technology relates to three-dimensional biomimetic platforms for culturing patient specific cells and tissues in biological material that closely recapitulates the native in vivo environment. The platforms of the present technology enable rapid and flexible biochemical, genomic, and metabolic analysis using a wide variety of assays, and live or end-point biological imaging.

The present invention relates to a 3D bioprinted skin tissue model, a method for providing said model and the use of said model. The 3D bioprinted skin tissue model comprises at least one bioink A, at least one cell type A, at least one factor A, wherein the bioink A comprises at least one biopolymer, a thickener, at least one extra-cellular matrix or a decellularized matrix, and optionally a photo initiator and/or cellular additions, the at least one cell type A is an epidermal, dermal and/or hypodermal cell or cell line, and the at least one factor A is a growth factor, protein and/or molecule that stimulates altered or abnormal metabolism of cell type A.

The disclosure provides methods of making and systems comprising a brain organoid operably connected to a controlled device such that the brain organoid controls the controlled device.

Air-liquid interface organoid cultures are initiated from human small intestine biopsy tissue comprising both the synintestinal epithelium and native intestinal immune cells, without reconstitution, which may be obtained from an individual pre-disposed or suffering from celiac disease. The organoid cultures exhibit T cell activation in response to in vitro gluten challenge and provide tools for a novel diagnostic method for celiac disease. Diagnosis may comprise the addition of immunogenic gluten-derived peptides into the organoid cultures, and assessing hallmarks of active celiac disease, including without limitation: 1) gliadin-presentation, resulting T-cell responses, such as 2) expansion and 3) activation, 4) epithelial-cell death and consequent 5) increased proliferative epithelial cell responses to gliadin. Celiac patients, either in GRD or GFD, test positive for these tests. In other embodiments the organoids are used to test responses to candidate therapeutic agents, assessing reduction of gliadin-dependent (1) T cell activation or expansion, or (2) organoid epithelial cell death.

The disclosure provides for multilayered organ-on-a-chip systems that can be used to generate topographic neural organoids, and uses thereof, including as models to study neurological disorders.

The present invention relates to a method of selecting a cancer organoid having resistance to an anticancer agent and/or radiation from a subject with cancer, and using the same.

Methods fabricate an endothelialized myocardium usable for screening of a drug. A microfibrous hydrogel scaffold is manufactured with additive manufacturing that concurrently bioprints endothelial cells directly within the microfibrous hydrogel scaffold. A bioink is bioprinted into an arrangement of one or more microfibers. The bioink includes at least one crosslinking component and suspended endothelial cells. The crosslinking component or components are crosslinked to yield the microfibrous hydrogel scaffold having the endothelial cells embedded directly within. The microfibrous hydrogel scaffold is seeded with cardiomyocytes to yield the endothelialized myocardium with a controlled anisotropy. The endothelialized myocardium can be incubated until the endothelialized myocardium matures into spontaneously beating myocardial tissue having contractions aligned with the controlled anisotropy. The beating myocardial tissue can be used to screen a drug when the beating myocardial tissue is embedded within a microfluidic perfusion bioreactor.